These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32351985)

  • 1. Prognostic Values of Transforming Growth Factor-Beta Subtypes in Ovarian Cancer.
    Zhou J; Jiang W; Huang W; Ye M; Zhu X
    Biomed Res Int; 2020; 2020():2170606. PubMed ID: 32351985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic values of
    Chetry M; Li S; Liu H; Hu X; Zhu X
    Biosci Rep; 2018 Apr; 38(2):. PubMed ID: 29472315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated expression of Tweety homologue 3 predicts poor clinical outcomes in ovarian cancer.
    Zhou J; Xu Y; Chen X; Chen F; Zhang J; Zhu X
    J Cancer; 2021; 12(23):7147-7157. PubMed ID: 34729116
    [No Abstract]   [Full Text] [Related]  

  • 4. The prognostic values of the peroxiredoxins family in ovarian cancer.
    Li S; Hu X; Ye M; Zhu X
    Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30104402
    [No Abstract]   [Full Text] [Related]  

  • 5. Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition.
    Do TV; Kubba LA; Du H; Sturgis CD; Woodruff TK
    Mol Cancer Res; 2008 May; 6(5):695-705. PubMed ID: 18505915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of the lysyl oxidase family in ovarian cancer.
    Ye M; Zhou J; Gao Y; Pan S; Zhu X
    J Clin Lab Anal; 2020 Dec; 34(12):e23538. PubMed ID: 33058284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma.
    Bristow RE; Baldwin RL; Yamada SD; Korc M; Karlan BY
    Cancer; 1999 Feb; 85(3):658-68. PubMed ID: 10091739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
    Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
    Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
    Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
    Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Title Prognosis Significance of ZEB2 and TGF-β1 as well as Other Clinical Characteristics in Epithelial Ovarian Cancer.
    Yan Z; Tian X; Wang R; Cheng X; Mi J; Xiong L; Wang Y; Deng J; Jia M
    Int J Gynecol Cancer; 2017 Sep; 27(7):1343-1349. PubMed ID: 30814239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of RRBP1 in epithelial ovarian cancer and its clinical significance.
    Ma J; Ren S; Ding J; Liu S; Zhu J; Ma R; Meng F
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31285390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunolocalizations of VEGF, its receptors flt-1, KDR and TGF-beta's in epithelial ovarian tumors.
    Inan S; Vatansever S; Celik-Ozenci C; Sanci M; Dicle N; Demir R
    Histol Histopathol; 2006 Oct; 21(10):1055-64. PubMed ID: 16835828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of transforming growth factors-beta1, -beta2 and -beta3 in human colon carcinoma.
    Bellone G; Carbone A; Tibaudi D; Mauri F; Ferrero I; Smirne C; Suman F; Rivetti C; Migliaretti G; Camandona M; Palestro G; Emanuelli G; Rodeck U
    Eur J Cancer; 2001 Jan; 37(2):224-33. PubMed ID: 11166150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and secretion of TGF-beta isoforms and expression of TGF-beta-receptors I, II and III in normal and neoplastic human breast.
    Chakravarthy D; Green AR; Green VL; Kerin MJ; Speirs V
    Int J Oncol; 1999 Jul; 15(1):187-94. PubMed ID: 10375614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of GPNMB predicts an unfavorable outcome of epithelial ovarian cancer.
    Ma RQ; Tang ZJ; Ye X; Cheng HY; Sun KK; Chang XH; Cui H
    Arch Gynecol Obstet; 2018 May; 297(5):1235-1244. PubMed ID: 29428978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High IGF2 expression is associated with poor clinical outcome in human ovarian cancer.
    Dong Y; Li J; Han F; Chen H; Zhao X; Qin Q; Shi R; Liu J
    Oncol Rep; 2015 Aug; 34(2):936-42. PubMed ID: 26063585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic values of signal transducers activators of transcription family in ovarian cancer.
    Li S; Sheng B; Zhao M; Shen Q; Zhu H; Zhu X
    Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28536310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prohibitin: targeting peptide coupled to ovarian cancer, luteinization and TGF-β pathways.
    El-Etreby NM; Ghazy AA; Rashad R
    J Ovarian Res; 2017 Apr; 10(1):28. PubMed ID: 28427435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
    Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
    Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic role of overexpressed Bromodomain and extra-terminal family in ovarian cancer.
    Chetry M; Bhandari A; Lin Y
    J Cancer; 2022; 13(5):1695-1705. PubMed ID: 35371325
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.